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A homozygous missense variant 
in the alkaline phosphatase gene 
ALPL is associated with a severe 
form of canine hypophosphatasia
Kaisa Kyöstilä  1,2,3, Pernilla syrjä1, Anu K. Lappalainen4, Meharji Arumilli  1,2,3, 
sruthi Hundi1,2,3, Veera Karkamo5, Ranno Viitmaa4, Marjo K. Hytönen1,2,3 & Hannes Lohi1,2,3
Inherited skeletal disorders affect both humans and animals. In the current study, we have performed 
series of clinical, pathological and genetic examinations to characterize a previously unreported 
skeletal disease in the Karelian Bear Dog (KBD) breed. The disease was recognized in seven KBD 
puppies with a variable presentation of skeletal hypomineralization, growth retardation, seizures 
and movement difficulties. Exome sequencing of one affected dog revealed a homozygous missense 
variant (c.1301T > G; p.V434G) in the tissue non-specific alkaline phosphatase gene, ALPL. The 
identified recessive variant showed full segregation with the disease in a cohort of 509 KBDs with a 
carrier frequency of 0.17 and was absent from 303 dogs from control breeds. In humans, recessive 
and dominant ALPL mutations cause hypophosphatasia (HPP), a metabolic bone disease with highly 
heterogeneous clinical manifestations, ranging from lethal perinatal hypomineralization to a relatively 
mild dental disease. Our study reports the first naturally occurring HPP in animals, resembling the 
human infantile form. The canine HPP model may serve as a preclinical model while a genetic test will 
assist in breeding programs.
The genetic skeletal diseases are a group of inherited conditions that affect the bone and cartilage tissues. 
Although they are individually rare, their collective impact on welfare is significant, both in man and animals. In 
humans, the most recent update on genetic skeletal disorders encompasses more than 400 distinct conditions, 
resulting from defects in over 350 different genes1. One such condition is hypophosphatasia (HPP), a metabolic 
bone disease characterized by defective skeletal mineralization2,3.
HPP is caused by mutations in the alkaline phosphatase gene ALPL, which encodes an alkaline phosphatase 
isozyme, liver/bone/kidney-type, commonly referred to as tissue non-specific alkaline phosphatase TNSALP 
(alternatively TNALP or TNAP)4,5. The alkaline phosphatases (ALPs, phosphate-monoester phosphohydrolase, 
alkaline optimum; EC 3.1.3.1) constitute a family of metalloenzymes that in tissues localize to the cell’s outer 
membrane, where they dephosphorylate a variety of substrates, releasing inorganic phosphate (Pi)6,7. Today, the 
number of HPP-associated ALPL variants in humans has reached 370 (http://www.sesep.uvsq.fr/03_hypo_muta-
tions.php), and the disease phenotype has also been recapitulated in mouse models8–11. The majority of human 
HPP patients are compound heterozygotes with a unique causative genotype, however, the disease can also be 
inherited in an autosomal dominant fashion, which is more frequent in milder disease forms and is associated 
with incomplete penetrance12.
The allelic heterogeneity of human HPP is reflected on the clinical spectrum, which ranges from stillbirth to a 
mild disease of the adulthood12. The disease is typically classified (in decreasing order of severity), into perinatal, 
infantile, childhood and adult onset forms, as well as into odonto-HPP, which is the mildest subtype affecting 
only teeth13–16. The major clinical characteristic of HPP is hypomineralization of bone and teeth, which results in 
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defective ossification, osteomalacia and premature loss of dentition3,17. However, patients can also suffer from sev-
eral accompanying clinical complications, such as respiratory failure, seizures, short stature, hypotonia, fractures 
and musculoskeletal pain14,15. The perinatal form corresponds to the most severe clinical picture with profound 
skeletal hypomineralization and the poorest prognosis15,18,19. In recent years, enzyme replacement therapy, using 
a recombinant TNSALP protein (asfotase alfa), has given promising results in the treatment of HPP patients20–22.
Purebred dogs (Canis lupus familiaris) are affected with a high number of naturally occurring genetic disor-
ders that are often breed-specific or found only in a few related breeds. This is a consequence of historic popula-
tion bottlenecks, inbreeding and genetic isolation of breeds23,24. Regarding inherited skeletal disorders, genetic 
studies in dogs have revealed shared disease genes with humans25–28 as well as novel gene-phenotype associa-
tions29,30. In the present study, we aimed to elucidate the clinical, pathological and genetic aspects of an inherited 
skeletal disease found in the Karelian Bear Dog (KBD) breed. The KBD is a Finnish primitive-type hunting dog 
that originates from the Karelia region of present-day Russia and is still actively used to hunt large game. We have 
previously recognized another genetic skeletal disorder in KBDs, a disproportionate chondrodysplastic dwarf-
ism, caused by a homozygous nonsense variant in the integrin gene ITGA1029. In the current work, we were able 
to define the second skeletal phenotype in the breed as HPP, which now represents the first report of naturally 
occurring HPP in animals.
Results
Clinical and radiographic examinations reveal a severe skeletal disease. Our research group was 
approached by a KBD breeder concerning a 10-week-old puppy from a litter of nine (litter 1) that had started to 
fall behind in growth at the age of 7 weeks and now had marked difficulties in walking (Supplementary Video 1). 
Two littermates of the 10-week-old affected dog had already died at the ages of 3 and 9 weeks without being 
clinically examined. However, the puppy that had died at 9 weeks of age was reported to have shown similar 
movement difficulties as the living affected dog. The living puppy was referred for clinical examination at the 
age of 12 weeks. On admission, the puppy presented with a crouched stance and reluctance to move (Fig. 1a), as 
well as a generalized muscle weakness, deformed elbow joints on palpation and hyperextension of distal joints. 
The cognition of the puppy appeared unaffected. Proprioceptive reactions were normal and flexor reflexes fairly 
strong, although the latter needed a strong stimulus. Euthanasia was elected due to the severity of the clinical 
signs. Radiographs of spine, skull and limbs were obtained after euthanasia, revealing severe skeletal abnormali-
ties (Fig. 1b–e). The most notable changes included thinned, hourglass-shaped diaphyses and poorly mineralized 
epiphyses and carpal and tarsal bones (Fig. 1d,e).
During the course of the study, we were notified of two additional KBD litters with altogether five affected 
puppies (four in litter 2 and one in litter 3) that failed to grow similarly to their littermates. At 2 weeks of age, 
their mean body weight was 646 g (range: 507–902 g), when the average weight of their unaffected littermates was 
around 1200 g. However, these five puppies were younger than the initially recognized affected dog, and they all 
had started showing seizures at the age of 2 weeks (Supplementary Video 2). Serum biochemistry profiles were 
obtained from one affected 2-week-old male puppy and its unaffected male littermate (litter 2) (Supplementary 
Table 1). The serum analysis revealed elevated total serum protein, albumin and urea levels in the affected dog, 
which were likely due to clinical dehydration. In addition, when compared to the unaffected sibling, the affected 
puppy showed a notably decreased serum ALP activity (affected = 10 U/l; control = 98 U/l; adult ref. 20–150 U/l) 
and an elevated calcium level (affected = 3,09 mmol/l; control = 2,86 mmol/l; adult ref. 2.15–2.95 mmol/l). The 
affected puppies were euthanized due to their poor condition and referred to a pathological examination at the 
ages of 14 and 20 days (litter 2 and 3, respectively). Radiographic examination was performed after euthanasia 
for the four affected puppies in litter 2. The radiographic findings were mostly unremarkable when compared to 
those of the 12-week-old puppy from litter 1. However, defective mineralization was noted in carpal and small 
tarsal bones, as well as in epiphyseal areas (Supplementary Fig. 1). Consistent with autosomal recessive mode of 
inheritance, both sexes were affected. The parents of affected dogs were not clinically examined, but their owners 
did not report of any related health problems.
Pathological examinations reveal a mineralization and ossification defect. Upon macroscopic 
examination, the oldest puppy from litter 1 showed marked skeletal changes, namely diaphyseal hypoplasia of 
long bones (Fig. 2a), which corresponded to the hourglass-like appearance seen in radiological examination. 
The metaphyses and epiphyses of long bones also showed macroscopic abnormalities, such as persisting primary 
spongiosa within the metaphyses (Fig. 2a). The skeletal changes were milder in the affected puppies from litters 2 
and 3 but some macroscopic findings were noted. Similar to the older affected dog, deficient remodelling of pri-
mary spongiosa was detected. In addition, three affected puppies from litter 2 showed cerebellar herniation into 
foremen magnum (Fig. 2b), a consequence of occipital bone hypoplasia and raised intracranial pressure.
Histologic examination of skeletal tissue revealed similar changes in all affected dogs. Within the diaphyseal 
and epiphyseal areas of long bones, abnormal bone tissue structure was evident (Fig. 2c,d). Interestingly, the 
thyroid gland of affected dogs was hypertrophic due to hyperplasia of interfollicular, calcitonin-producing C cells 
(Fig. 2e–g), a change that occurs as a result of prolonged hypercalcemia31. This finding was present in all affected 
dogs but most prominent in the oldest affected puppy from litter 1. Furthermore, puppies from litter 2 and 3 had 
mild cerebral oedema, as well as acute lesions related to the cerebellar coning, such as cortical neuronal necrosis 
in the caudoventral cerebellar vermis. Macroscopic and histologic examination of teeth did not reveal specific 
findings in the affected dogs. Overall, the pathological findings in affected dogs were compatible with a gener-
alized skeletal ossification and mineralization defect. The specific finding of C cell hyperplasia was indicative of 
long-term hypercalcemia and compatible with the elevated serum calcium level measured in one affected puppy.
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Exome sequencing reveals a candidate variant in the ALPL gene. To identify the genetic cause of 
the disease, we performed whole exome sequencing for the 3-month-old affected puppy from litter 1. The exome 
variant data from the affected dog was filtered against 242 control exomes and 658 genomes (Supplementary 
Table 2), resulting in 346 homozygous case-specific variants. From these variants, we prioritized 25, including 
all that were predicted to have a protein level impact. Another 10 variants were omitted as they were found in 
homozygous state in sequence variant data from 13 unaffected KBDs. The remaining 15 variants (Supplementary 
Table 3) were reviewed in more detail, revealing one highly promising causative candidate, a missense change, 
c.1301T > G; p.V434G, in the ALPL gene (XM_005617214.3, XP_005617271.1).
We proceeded to validate the association between the ALPL variant and disease in larger cohorts. DNA sam-
ples were obtained from altogether seven affected KBDs, comprising the 3-month-old proband, its sibling that 
had died at 9 weeks of age, and the five younger puppies from litters 2 and 3. Sanger sequencing of the ALPL var-
iant revealed all seven puppies to be homozygous for the missense change (Fig. 3). Furthermore, all dogs from a 
cohort 281 control KBDs were either heterozygous or wild-type dogs. We then used a Taqman assay to genotype 
an additional set of 221 unaffected KBDs and a cohort of 303 control dogs from eight different Nordic breeds. 
Figure 1. Radiographic findings in a 3-month-old affected dog. (a) The oldest affected dog (litter 1) had a 
crouched, planti- and palmigrade stance and gait. (b) Laterolateral radiograph of the head. Both maxilla and 
mandible are shortened and the lower jaw is malformed with an angulated mandibular body and an elongated 
mandibular ramus (arrowhead). (c) Laterolateral radiograph of the lumbar spine. The vertebral bodies are short, 
the end plates are poorly mineralized and the dorsal borders of the vertebral spinous processes are irregular. 
Mediolateral radiograph of (d) the right front and (e) right hind limbs. The long bones are hourglass-shaped 
(open arrowheads) and have hypoplastic marrow cavity, as well as hypoplastic cortical bone. Carpal bones and 
distal femoral epiphyses show irregular mineralization (arrowheads).
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The second KBD set did not contain any new variant homozygotes, and all dogs from the other breeds had the 
reference genotype (Table 1). Overall, these results indicated a full segregation between the ALPL variant and 
the disease. Finally, in order to rule out potential confounding effects on the phenotype, we screened the affected 
puppies for the previously reported ITGA10 mutation that causes chondrodysplasia in the breed29. The mutation 
allele was not found in the affected dogs.
the ALPL variant is located on a conserved protein domain. The identified c.1301T > G change 
was located on exon 11 of the canine ALPL gene, resulting in a valine to glycine amino acid change, p.V434G, 
in the encoded TNSALP protein (Fig. 4a). In both humans and dogs, the ALPL gene is composed of 12 exons, 
eleven of which are protein coding. The full length TNSALP protein shows 90% sequence identity between the 
two species, and differs in length by one amino acid, 524 residues in humans (NP_000469.3) and 525 in dogs 
(XP_005617271.1). The TNSALP polypeptide folds into a cell surface homodimer that contains several known 
domains, including an active site, homodimeric interface, a calcium-binding site and a crown domain32–34. The 
Figure 2. Pathological findings in canine hypophosphatasia. (a) A cross section of a formalin fixed femur 
from a 3-month-old affected puppy (litter 1). The femur has a striking hourglass appearance. The diaphyseal 
periosteum and cortex are abnormally broadened by unmineralized osteoid and fibrous tissue, and the marrow 
cavity is narrowed due to defective modelling of primary spongiosa (encircled). Retained epiphyseal cartilage 
(open arrowhead) and irregular growth lines (arrowhead) are seen within the epiphyseal areas. (b) Formalin-
fixed cerebellum of a 2-week-old affected puppy (litter 2). The cerebellar vermis is protruding into the spinal 
canal (arrowhead). (c) Longitudinal section of diaphyseal cortex, decalcified, HE 50X. The periosteal cambium 
(C) is thickened and cellular, with an underlying broad zone of unmineralized woven bone (W) and a cortex 
consisting of lamellar bone (L) instead of compact bone. The periosteal fibrous layer (F) appears normal. (d) 
Articular cartilage and epiphysis, decalcified, HE 50X. The ossification front is uneven (line) and irregular 
tongues of retained poorly mineralized cartilage (arrowheads) are present within the epiphysis. (e) Thyroid 
gland from an affected puppy, HE 200X. The C-cells are numerous and hypertrophic between the colloid 
follicles. (f) Thyroid gland from an affected puppy, calcitonin IHC 200X. Profound C-cell hypertrophy and 
hyperplasia is noted. (g) Thyroid gland of an unaffected, age- and gender matched puppy, calcitonin IHC 200X. 
A few C-cell groups and scattered single calcitonin-rich C-cells are seen. All histopathological images (c–g) are 
from the 3-month-old affected puppy (litter 1).
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homozygous p.V434G change in affected dogs was found to be located within the crown domain, more specifi-
cally, on the first residue of a reported 16 amino acid long collagen binding site34 (Fig. 4b,c). We utilized the ALPL 
Gene Mutation Database (http://www.sesep.uvsq.fr/03_hypo_mutations.php) and the Genome Aggregation 
Database (gnomAD)35 to determine whether any variants have been identified in the Val434 position in humans. 
No such variants were found, but multiple disease-causing mutations were reported in the surrounding sequence 
(Fig. 4b).
The evolutionary conservation of the Val434 was assessed through protein sequence alignments, revealing the 
Val434 position to be conserved in mammals, as well as in most other vertebrate species (Fig. 4b, Supplementary 
Fig. 2). In-silico pathogenicity predictions tools yielded both neutral and deleterious predictions for the p.V434G 
change (Supplementary Table 4). The PredictSNP tool36, which calculates a consensus estimate from several dif-
ferent algorithms, produced a non-pathogenic prediction (with four neutral and three deleterious predictions). 
Figure 3. A disease pedigree constructed around the affected dogs. The ALPL genotypes are denoted with 
different colours. Several inbreeding loops and common ancestors are present. Within the affected litters, 
samples were obtained from altogether three parents and twelve unaffected full siblings. In both litters 1 and 
2, one puppy had died without sampling or clinical and pathological examinations, at the age of 3 weeks (litter 
1) and 2 days (litter 2). The genotype and possible affection status of these puppies could not therefore be 
determined.
Breed N T/T T/G G/G
Karelian Bear Dog 509 417 (82%) 85 (17%) 7 (1%)
Norwegian Elkhound 88 88 — —
Finnish Spitz 56 56 — —
Norrbottenspets 42 42 — —
Jämthund 40 40 — —
Finnish Lapphund 31 31 — —
East Siberian Laika 20 20 — —
West Siberian Laika 13 13 — —
Russo-European Laika 13 13 — —
Total 812 720 85 7
Table 1. ALPL c.1301T > G genotypes in breed cohorts.
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Figure 4. A missense change in the canine ALPL gene. (a) Sequence chromatograms of the ALPL c.1301T > G 
variant in exon 11 and a schematic representation of the ALPL gene. (b) Structure of the TNSALP polypeptide and 
multiple sequence alignment of the variant position in 18 mammalian species. Amino acid residues that make up 
the active site and the homodimerization interface are scattered along the polypeptide chain, whereas the calcium 
binding site and the crown domain form separate entities34. The p. V434G missense change is located within the 
crown domain. Those amino acid residues that contain HPP-associated variants in humans are marked on top of 
the alignment and highlighted in grey (http://www.sesep.uvsq.fr/03_hypo_mutations.php). (c) Side and top views 
of the three-dimensional (3D) structure of the TNSALP homodimer, modelled from the crystal structure of the 
human placental alkaline phosphatase32. The two monomers are separated by different colours. The Val434 position 
is denoted with yellow, the active site residues with red and the collagen binding motif with black. The crown 
domain forms a flexible loop structure on top of the homodimer.
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The PROVEAN algorithm37 also produced a neutral prediction, whereas the MutationTaster2 algorithm38 pre-
dicted the p.V434G variant to be disease causing with a very high probability.
Urine analysis reveals elevated phosphoethanolamine (PEA) levels. In humans, the urine excre-
tion of alkaline phosphatase substrate phosphoethanolamine (PEA) is used as a supporting tool in diagnosing 
HPP3,39. We collected urine samples from three affected dogs during necropsy, from the oldest affected dog in 
litter 1 and two younger puppies in litter 2. Urine PEA levels were measured from the three affected dogs and 
from four age-matched control dogs euthanized for other reasons. In support of our genetic findings, all affected 
KBD puppies excreted markedly elevated levels of PEA (x  579 mmol/mol Crea, range: 300–760) in comparison to 
the control dogs (x  6,02 mmol/mol Crea, range: 1.46–15.6).
Discussion
In the present study, we recognize a novel genetic skeletal disease in dogs and identify a homozygous missense 
change in the ALPL gene. ALPL mutations cause HPP in humans and the clinical and pathological findings in the 
affected dogs are compatible with the human disease, particularly the infantile form. Besides the clinicopatho-
logical similarities, strong genetic and biochemical evidence of canine HPP was obtained: a fully segregating 
breed-specific recessive missense variant in a conserved protein domain, combined with serum and urine find-
ings typical for HPP patients.
In humans, most of the known ALPL mutations are missense changes (73%) (http://www.sesep.uvsq.fr/03_
hypo_mutations.php), which was also the case with the identified canine variant (c.1301T > G; p.V434G). 
Pathogenicity predictions did not yield a conclusive estimate for the functional impact of the variant, which is 
likely in part due to the conservative nature of the Val to Gly amino acid change. In human HPP patients, several 
conservative missense changes (e.g. p. A40V, p.G326V and p.A377V) have been reported across the TNSALP 
protein (http://www.sesep.uvsq.fr/03_hypo_mutations.php). This suggests that the protein may be particularly 
vulnerable even to milder amino acid changes, although, the location of the change does play a role. The canine 
p.V434G variant was positioned within the crown domain of the encoded TNSALP protein. The 65 residues long 
crown domain is considered essential for protein function, influencing several properties such as enzyme stability 
and collagen-binding32,34,40,41. Our sequence alignments and previous evolutionary analysis34 indicate that the 
Val434 position is conserved in mammals and other tetrapods, suggesting that the residue possesses functional 
significance in higher vertebrates. Causative variants have not been reported in the Val434 position in humans, but 
several disease-causing mutations affect other residues of the crown domain34. The Val434 residue marks the start 
of a 16 amino acid long collagen-binding site34, and whether the canine variant might affect the collagen binding 
properties of the TNSALP homodimer, can only be speculated at this point. In humans, several missense variants 
associated with severe HPP have been shown to result in degradation of the mutant protein by the proteasome 
system42.
The biochemical hallmark of HPP is reduced level of circulating ALP activity, which is inversely correlated 
with disease severity43,44. In humans, ALP activity is higher in children than in adults45, which is also true for 
dogs46,47. However, unlike in humans, age-dependent normal ranges are not available for routine biochemistry 
tests in dogs. We therefore utilized an unaffected sex-matched littermate to help interpret the blood biochemistry 
results, which revealed the serum ALP level to be nearly 10x lower in the affected 2-week-old puppy than in the 
healthy sibling. In HPP, the compromised ability of TNSALP to dephosphorylate its natural substrates results in 
their extracellular accumulation. Increased levels of TNSALP substrates, inorganic pyrophosphate (PPi), pyri-
doxal 5′-phosphate (PLP) and PEA, has been documented in HPP patients39,48–50. In accordance with this, urine 
analysis uncovered markedly elevated PEA excretion in affected dogs. Although, in terms of HPP pathophysiol-
ogy, PPi accumulation is considered to be the major pathological mechanism. During bone growth and devel-
opment, TNSALP is present in osteoblasts and chondrocytes, as well as in osteoblast- and chondrocyte-derived 
matrix vesicles that serve as the initial site through which mineral is formed and propagated into the collagenous 
extracellular matrix. The excess amount of unhydrolyzed PPi is thought to inhibit the process of embedding 
hydroxyapatite (calcium phosphate) crystals into the extracellular matrix, resulting in defective skeletal mineral-
ization11,51,52. A corresponding mechanism of teeth mineralization, involving MVs budding from odontoblasts, 
explains the dental phenotype in HPP patients53,54.
In humans, the ALPL genotype of HPP patients has been shown to correlate fairly well with the clinical phe-
notype55,56. However, variable expressivity has been reported in some patients with identical genotypes, and 
whether this variation is caused by genetic or epigenetic modifiers or other confounding factors is not known57. 
Phenotypic variation was also present in affected dogs, in which two clinical presentations were recognized. The 
earlier onset disease progressed to owner-elected euthanasia before 3 weeks of age due to seizures and failure 
to thrive (litters 2 and 3), whereas the other form became apparent after one month of age and developed into a 
generalized ossification defect (litter 1). In humans, seizures have been described in perinatal and infantile HPP 
and they serve as a strong indicator for a lethal outcome58. The underlying cause of the neonatal seizures is not 
well understood. However, in several cases, the seizures have been responsive to pyridoxine (vitamin B6) treat-
ment rather than to standard antiepileptic drugs59–63, which may be explained by the role of TNSALP in vitamin 
B6 metabolism. Extracellular PLP (the active form of vitamin B6) is dephosphorylated by TNSALP, enabling its 
uptake into cells as pyridoxal and subsequent rephosphorylation back to PLP64. Intracellular vitamin B6 functions 
as coenzyme in neurotransmitter metabolism, and therefore, low pyridoxal levels have been suggested to cause 
seizures through a defect in neurotransmitter synthesis8,60,65. In the affected KBDs, treatment of the seizures was 
not attempted.
Radiologic and histopathologic examinations of affected dogs revealed a skeletal mineralization and ossifica-
tion defect. Dental abnormalities were not detected. The skeletal changes were more severe in the oldest affected 
dog, including pronounced diaphyseal hypoplasia and generalized hypomineralization. The younger puppies had 
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milder skeletal changes, however, in three of them, cerebellar herniation was noted. In human infantile and child-
hood HPP, premature closure of the cranial sutures (craniosynostosis) is a common manifestation, which can lead 
to increased intracranial pressure and other complications, such as herniation of the cerebellar tonsils66. Another 
finding in the affected KBDs was hyperplasia of the thyroidal C cells. The C cells of the thyroid gland release the 
hormone calcitonin in response to elevated blood calcium levels, and in the case of prolonged hypercalcemia, C 
cell hyperplasia occurs31. This histological finding was supported by the increased serum calcium levels measured 
in one affected dog. Hypercalcemia is reported in human HPP patients as well, resulting from decreased entry of 
minerals into the skeleton. In extreme cases, this can lead to nephrocalcinosis and renal failure17. In the affected 
dogs, metastatic calcification of soft tissues was not detected.
In conclusion, our study reports a strong association between a skeletal mineralization defect in dogs and a 
recessive variant in a conserved domain of the ALPL gene. Together, our clinical, pathological and genetic find-
ings strongly suggest that the skeletal phenotype observed in affected dogs is HPP, resembling the infantile disease 
form in humans. Our findings represent the first report of naturally occurring HPP in animals and have enabled 
the development of a genetic test for breeding purposes.
Materials and Methods
Ethical approval. All dogs included in this study were privately owned pets. Sample collections, clinical 
examinations and animal necropsies were carried out with the dog owners’ informed consent. The experiments 
were approved by the Finnish national Animal Experiment Board (ESAVI/7482/04.10.07/2015) and performed 
in accordance with relevant guidelines and regulations.
Serum and urine analysis. Serum biochemistry profiles (albumin, alkaline phosphatase, alanine ami-
notransferase, amylase, total bilirubin, blood urea nitrogen, calcium, phosphorus, creatinine, glucose, sodium, 
potassium, total protein and globulin) were examined from one affected and one control puppy (Supplementary 
Table 1). Urine samples were obtained from three affected dogs (one puppy from litter 1 and two from litter 2) and 
three age-matched control dogs, euthanized due to cerebellar dysplasia (n = 2) and congenital hypothyroidism 
(n = 1). The samples were collected at autopsy via direct open cystocentesis. The amount of excreted phosphoeth-
anolamine (PEA) was analysed from the urine samples by high performance liquid chromatography (Synlab) and 
the urinary concentration differences were normalized against the amount of creatine.
Pathological examinations. One puppy from litter 1 underwent post-mortem examination at the 
Companion Animal Pathology Section in the Finnish Food Safety Authority Evira and six puppies were necrop-
sied at the Section of Veterinary Pathology, University of Helsinki. The puppy necropsied at Evira had died natu-
rally, whereas the other affected dogs were euthanized on their owners’ request. The post mortem examinations 
included gross examination of the body and organs, including sectioning of long bones and spine in selected 
cases. Histologic examination of brain and internal organs was performed for all puppies. Specific histological 
sampling of skeletal, dental and muscular tissue was carried out for six dogs after the candidate variant was identi-
fied. Fresh sampled tissues were formalin fixed, paraffin-embedded and routinely stained with hematoxylin-eosin 
(HE). To verify C-cell hyperplasia, thyroid glands were immunohistochemically stained with an anti-calcitonin 
antibody (ab 75368, prediluted Abcam).
Study cohorts and DNA samples. Canine samples were retrieved from the dog DNA bank at the 
University of Helsinki. The KBD cohort comprised altogether 509 dogs, including seven affected dogs (Table 1). 
The sample of one affected KBD puppy was received from Finnish Food Safety Authority Evira, where the ani-
mal had been necropsied. A control cohort of Nordic breeds comprised 303 dogs from eight different breeds 
(Table 1). Genomic DNA was isolated from EDTA blood or tissue (in the case of a few necropsied dogs) by using a 
semi-automated DNA extraction robot (PerkinElmer chemagen Technologie GmbH). DNA concentrations were 
measured by using either a Nanodrop ND-1000 UV/Vis Spectrophotometer (Nanodrop technologies) or a Qubit 
fluorometer (Thermo Fisher Scientific).
Pedigrees. Finnish Kennel Club’s pedigree registry KoiraNet (http://jalostus.kennelliitto.fi/) was utilized to 
retrieve pedigree information for the affected dogs and the GenoPro genealogy software (http://www.genopro.com/) 
was used to draw the disease pedigree.
Reference sequences. The dog genome build CanFam 3.1 was used in all analyses. The canine ALPL mRNA 
and protein reference sequences were XM_005617214.3 and XP_005617271.1, respectively.
Next generation sequencing. Whole exome sequencing of an affected dog was performed by using Roche 
NimbleGen SeqCap EZ target enrichment design 140702_canFam3_exomeplus_BB_EZ_HX1 with a capture size 
of ~152 Mb67. The sequencing was carried out at the Biomedicum Functional Genomics Unit (FuGU, University 
of Helsinki) using Illumina NextSeq500 technology. The Burrows-Wheeler Aligner (BWA) version 0.7.12-r103968 
was used to map the acquired reads and the Picard tools (http://broadinstitute.github.io/picard/) to sort the 
mapped reads and to mark duplicates. Indel realignment, base-quality score recalibration and variant calling was 
carried out using the Genome Analysis Tool Kit (GATK) HaplotypeCaller, version 3.5.069. The sequencing yielded 
~83 million 2 × 150 bp paired-end reads, of which 99,5% were mapped to the dog genome (CanFam 3.1) with 
a 60X mean coverage. Variant calling produced 883,008 single nucleotide variants and 292,075 small insertions 
and deletions. To identify potential causative variants in the affected dog, we performed variant filtering under 
the assumption of autosomal recessive inheritance and a breed-specific founder mutation. For this purpose, we 
used our in-house variant database, which was queried using Genotype Query Tools70. The entire sequence data 
cohort utilized in this study comprised altogether 252 whole exomes and 663 whole genomes from 903 animals, 
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including the exome of an affected KBD, as well as nine exomes and five genomes from 13 unaffected KBDs 
(Supplementary Table 2). However, the unaffected KBDs were omitted from the initial variant filtering step in 
case they were carriers of the causative variant. The dog and wolf genome SNP database (DoGSD)71 was utilized 
to retrieve 38 control genomes.
Variant validation. Sanger sequencing and Taqman genotyping were utilized to screen the ALPL variant in our 
study samples. Sanger sequencing primers, GTTCTCCAACCTGACTCCTG and AGAGAGGCAGAGTTCGCATG 
(5′ > 3′ forward and reverse, respectively), were designed with the Primer3 program (http://bioinfo.ut.ee/primer3/)72. 
PCR amplification was carried out by using Biotools DNA Polymerase (Biotools B&M Labs, S.A.) and sequencing 
reactions were performed at the Institute for Molecular Medicine Finland (FIMM). The Sequencher (version 5.2.4) 
program (Gene Codes Corporation) was used to analyse the resulting Sanger sequence data. A custom Taqman SNP 
genotyping assay was utilized to genotype additional sample cohorts (ThermoFisher Scientific). The primer and probe 
sequences for the assay were the following: CGGTGAGCGAGAGAACGT and CCCAGCCCCGGATTTGG (5′ > 3′ 
forward and reverse, respectively), VIC-CCTCACCGTAGTCCACCAT and FAM-CTCACCGTAGTCCCCCAT 
(5′ > 3′ wild-type and variant allele, respectively). The Taqman genotyping reactions were carried out using Taqman 
Genotyping Master Mix (ThermoFisher Scientific) and Biorad’s CFX96 Touch Real-Time PCR Detection System. The 
ITGA10 variant was genotyped from the affected dogs by using Sanger sequencing as described previously29.
Bioinformatic analyses of the ALPL variant. To visualize the native structure of the TNSALP homodi-
mer, a three-dimensional (3D) model of the protein was retrieved from the SWISS-MODEL Repository (https://
swissmodel.expasy.org/). We utilized a model of the human TNSALP (UniProtKB accession: P05186) that had 
been constructed on the basis of the crystal structure of the human placental alkaline phosphatase (template ID: 
1zef.1 A)32. The 3D image was drawn by using the Discovery Studio 4.5 Visualizer (BIOVIA). Multiple sequence 
alignments of the TNSALP protein were constructed by using the Clustal Omega algorithm (https://www.ebi.
ac.uk/Tools/msa/clustalo/)73. The aligned protein sequences were retrieved from the Entrez protein database 
(https://www.ncbi.nlm.nih.gov/protein/) and their respective sequence identifiers are found in Supplementary 
Fig. 2. The pathogenicity of the ALPL variant was assessed through the PROVEAN (http://provean.jcvi.org/
index.php)37, PredictSNP (https://loschmidt.chemi.muni.cz/predictsnp1/)36 and MutationTaster2 (http://www.
mutationtaster.org/)38 algorithms. The first two programs were used with the canine ALPL reference sequence 
(XM_005617214.3, XP_005617271.1), whereas the latter was used with a human reference (NM_000478.5, 
NP_000469.3).
Data Availability
The exome sequence data of the affected dog has been submitted to the Sequence Read Archive (SRA) (https://
www.ncbi.nlm.nih.gov/sra) and will be available with a study accession SRP142577.
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